The study of efficacy of Empagliflozin on metabolic effects of atypical antipsychotic drugs in patients with psychiatric disorders: a randomized clinical trial

Abstract

The study of efficacy of Empagliflozin on metabolic effects of atypical antipsychotic drugs in patients with psychiatric disorders: a randomized clinical trial. Introduction: Antipsychotic medications are prescribed for mental disorders like psychosis and bipolar disorder; however, these medications can cause long term adverse effects like weight gain, diabetes mellitus type 2 (DM2), and metabolic disorders. Based on auspicious impacts of empagliflozin on weight, Blood sugar, and lipid profile, this study was designed to investigate effects on empagliflozin intake on antipsychoric medication’s adverse effects.Purpose: The aim of this study is to evaluate efficacy of empagliflozin intake in preventing adverse effects of antipsychotic medicines e.g. olanzapine, clozapine … in patients suffering from mental disorders.Methodology: This study is a randomized clinical trial that was conducted as a pilot study. Forty non-pregnant or non-breastfeeding patients with DSM-V-TR criteria, suffering from mental disorders were included in the study based on determined inclusion and exclusion criteria, and were randomly divided into two groups of 20 intervention and control (intervention group: group receiving medication). Atypical antipsychotics such as olanzapine, clozapine, and risperidone in combination with ampagliflozin (10 mg daily) for 12 weeks are the consumed medication in intervention group and atypical antipsychotic medication for 12 weeks are the only received prescription in control group. Both groups were carefully examined in terms of metabolic indicators including blood pressure, body weight, body mass index (BMI), waist circumference, fat profile (LDL-HDL-TG) and FBS at the beginning, fourth week, eighth week and end of the study.Results:The drug Empagliflozin can have a positive effect on weight, waist circumference, and BMI in patients who use atypical antipsychotics and can reduce them.Conclusion:Empagliozin can reduce fasting blood sugar, which has been observed in this study. Although comparison of lipid profile and blood pressure did not change significantly.